Skip to main content

Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?



Sclerostin, secreted by osteocytes, plays a key role in antagonizing bone formation. Recent studies, which seldom include chronic kidney disease (CKD) patients, have reported on the association of sclerostin and mortality, with contradictory results. The assay-linked variability may contribute to these discrepant results.


We have compared sclerostin results obtained with two assays (TECO and Biomedica) in a cohort of 91 CKD patients undergoing hemodialysis.


We found a strong correlation (r = 0.870, p < 0.0001) between the serum sclerostin concentrations measured by the two assays. Bland–Altman plot shows that, although there was a partial agreement between the assays, differences found for individual values (−0.27 ± 0.54; ranging from −1.3 to 0.8 ng/ml) were quite unpredictable. By using TECO, there was a significant relationship between serum sclerostin, and calcitonin (r = 0.224), IL-6 (r = 0.251) and FGF23 (r = 0.331) levels while no correlation was found with PTH or total alkaline phosphatase. Regarding Biomedica, there was a significant correlation with calcitonin (r = 0.260), and β2 microglobulin (r = 0.210), but no correlation with PTH or total alkaline phosphatase. Overall, 25.3 % among the patients had different classifications as to normal or high values, according to the manufacturer.


Sclerostin levels should be interpreted with caution, as they can vary widely according to the assay used. Further studies are clearly needed before considering sclerostin as a true marker of mortality. Moreover, we do not know at present which serum sclerostin levels should be regarded as either normal or potentially dangerous in patients with CKD.

This is a preview of subscription content, access via your institution.

Fig. 1


  1. 1.

    Compton JT, Lee FY (2014) A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am 96(19):1659–1668. doi:10.2106/JBJS.M.01096

    Article  PubMed  Google Scholar 

  2. 2.

    Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA, on behalf of the European Uremic Toxin Work G (2014) Uremic toxicity and sclerostin in chronic kidney disease patients. Nephrol Ther. doi:10.1016/j.nephro.2014.04.002

    PubMed  Google Scholar 

  3. 3.

    Clarke BL, Drake MT (2013) Clinical utility of serum sclerostin measurements. BoneKEy Rep 2:361. doi:10.1038/bonekey.2013.95

    Article  PubMed Central  PubMed  Google Scholar 

  4. 4.

    Dawson-Hughes B, Harris SS, Ceglia L, Palermo NJ (2014) Serum sclerostin levels vary with season. J Clin Endocrinol Metab 99(1):E149–E152. doi:10.1210/jc.2013-3148

    Article  PubMed Central  PubMed  Google Scholar 

  5. 5.

    Goncalves FL, Elias RM, Dos Reis LM, Graciolli FG, Zampieri FG, Oliveira RB, Jorgetti V, Moyses RM (2014) Serum sclerostin is an independent predictor of mortality in hemodialysis patients. BMC Nephrol 15(1):190. doi:10.1186/1471-2369-15-190

    Article  PubMed Central  PubMed  Google Scholar 

  6. 6.

    Viaene L, Behets GJ, Claes K, Meijers B, Blocki F, Brandenburg V, Evenepoel P, D’Haese PC (2013) Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Nephrol Dial Transplant 28(12):3024–3030. doi:10.1093/ndt/gft039

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Drechsler C, Evenepoel P, Vervloet MG, Wanner C, Ketteler M, Marx N, Floege J, Dekker FW, Brandenburg VM, for the NSG (2014) High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. doi:10.1093/ndt/gfu301

    Google Scholar 

  8. 8.

    Delanaye P, Krzesinski JM, Warling X, Moonen M, Smelten N, Medart L, Bruyere O, Reginster JY, Pottel H, Cavalier E (2014) Clinical and biological determinants of sclerostin plasma concentration in hemodialysis patients. Nephron Clin Pract. doi:10.1159/000366449

    PubMed  Google Scholar 

  9. 9.

    Costa AG, Cremers S, Dworakowski E, Lazaretti-Castro M, Bilezikian JP (2014) Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos Int 25(5):1547–1554. doi:10.1007/s00198-014-2635-3

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R (2013) Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 98(9):3873–3883. doi:10.1210/jc.2013-2113

    Article  CAS  PubMed  Google Scholar 

  11. 11.

    Bielesz BO, Hempfing T, Kieweg H, Marculescu R, Haas M, Cejka D (2014) Sclerostin declines during hemodialysis and appears in Dialysate. Blood Purif 38(1):30–36. doi:10.1159/000364992

    Article  CAS  PubMed  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Rosa M. A. Moysés.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Moysés, R.M.A., Jamal, S.A., Graciolli, F.G. et al. Can we compare serum sclerostin results obtained with different assays in hemodialysis patients?. Int Urol Nephrol 47, 847–850 (2015).

Download citation


  • Chronic kidney disease
  • Dialysis
  • Sclerostin
  • Sclerostin assays
  • Mortality